What does on-label and off-label actually restrict?
What "label" refers to, and what it does and doesn't restrict about promotional claims.
The label is the approved prescribing information for a drug: the indications it's approved to treat, the population it's approved for, and the dosing that approval covers. On-label means a claim stays inside what the label actually says. Off-label means it doesn't, regardless of whether the underlying clinical fact is true.
What it is
A drug can have real, published evidence for a use that isn't on its label, and promoting that use is still off-label promotion. The label isn't a summary of everything known about a drug. It's the specific, regulator- approved scope a promotional claim is allowed to stay inside. Evidence outside that scope might be real, but it isn't promotable.
This trips people up because it sounds like a factual-accuracy rule and it isn't one. A statement can be scientifically accurate and still be off-label, if the label's approved scope doesn't cover the population, the indication, or the dosing the statement describes.
Why it matters
This is one of the most common reasons a claim gets flagged in MLR review, and it's rarely because someone proposed something false. It's because a benefit that's real for one population got generalized into a claim that reads as if it applies more broadly than the label actually permits.
For anyone drafting content, the practical habit is to check the specific population and indication a claim is being made about against the label's actual scope, every time, rather than assuming a claim is fine because the underlying data is solid.
How it actually works
A few patterns worth knowing:
- Indication scope: a drug approved for one condition can't be promoted for a related but distinct condition, even with supporting data, until that indication is separately approved.
- Population scope: a drug approved for adults generally can't be promoted for a pediatric population based on adult data alone.
- Dosing scope: promoting a dose or regimen outside what's approved is off-label, even if it's a dose studied in a published trial.
Medical Affairs teams can typically respond to an unsolicited off-label question from a healthcare professional. That's a different activity from promotion, and the two are governed by different rules. This distinction (a proactive promotional claim versus a reactive medical information response) is one of the more consequential ones in day-to-day pharma marketing operations.
Common misunderstandings
The most common misunderstanding is treating "true" and "on-label" as the same test. They aren't. A second common one is assuming label scope is static: labels get updated (a new indication approved, a new population added), so what was off-label a year ago may be on-label now, and checking the current label rather than relying on memory matters.
This explainer covers the general mechanics. It isn't legal advice, and specific label scope varies by drug, by market, and over time. Confirm current label language with a qualified regulatory or legal reviewer before treating anything here as a specific determination.
Related reading
Agentic AI in pharma marketing: what it is, and what it still needs a human for
The real difference between a single-prompt AI tool and an agentic one, and where human judgment still sits in the loop.
What is a Boxed Warning, and what triggers one
What a Boxed Warning actually signals, and the kinds of risk that lead the FDA to require one.